Ikarian Capital’s Coherus Oncology CHRS Stock Holding History

Ikarian Capital’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-84,100	Closed	-$1.36M	–	181
2020 Q1	$1.36M	Hold	84,100	–	–	0.1%	109
2019 Q4	$1.51M	Buy	+84,100	New	+$1.55M	0.25%	67

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ikarian Capital's CHRS Position: Q1 2024 in Review

Ikarian Capital sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 340,787 shares — an estimated $1.13M sold.

Ikarian Capital first reported a position in CHRS in Q3 2023 and held it in 2 quarters. The position peaked at $3.24M in Q3 2023. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

Ikarian Capital reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
Ikarian Capital sold 340,787 Coherus Oncology shares in Q1 2024, an estimated $1.13M.
Ikarian Capital first reported a position in Coherus Oncology in Q3 2023 and held it in 2 quarters.
Ikarian Capital's Coherus Oncology position peaked at $3.24M in Q3 2023.
137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.